Analysis on GLP-1 medicine for AUD and different substance use points has gained momentum in recent times.
“It is a time of cautious optimism within the subject,” says Joseph P. Schacht, PhD, an affiliate professor of psychiatry and substance dependence on the College of Colorado College of Medication Anschutz Medical Campus in Aurora. “A number of small scientific trials have discovered that GLP-1 RAs, in contrast with placebo, lowered alcohol use,” he provides.
Among the most compelling analysis:
- One examine, revealed in July 2026 in BMJ Open, in contrast the consequences of GLP-1s with authorised AUD medicine. For folks with weight problems, researchers discovered GLP-1 customers had a 65 % decrease danger of alcohol-related hospitalization than these taking AUD medicines.
- In a examine revealed in JAMA Psychiatry in February 2025 that included 48 sufferers with AUD, researchers discovered low-dose weekly injections of semaglutide considerably lowered alcohol cravings and nicotine use in contrast with placebo.
- In a big Swedish examine revealed in JAMA Psychiatry in November 2024, scientists discovered that individuals who have been taking the GLP-1 medicine semaglutide or liraglutide have been much less prone to be hospitalized for AUD.
- Early analysis has recommended that GLP-1s can also scale back cravings for different addictive substances, like cocaine.
”Whereas these and different research are encouraging, they’re nonetheless thought of preliminary,” says Dr. Schacht. “Particular measures like security, effectiveness, and dosing for AUD nonetheless should be examined and confirmed. In the end, we want extra knowledge from bigger scientific trials of those medicines. Luckily, a number of tutorial and trade trials ought to have leads to the subsequent one to 2 years.”
